Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease. The structural differences among newer second-generation anti-VEGF agents—and their implications for ...

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies. The lesion characteristics of patients ...

This study indicated that by analyzing the data of one of the most extensive GA patient cohorts in the Nordic countries, it established a data set on the long-term treatment-naive GA growth dynamics.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression. Results of a new study support the hypothesis that iron ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Feistmann in an overview of office-based surgery, with actionable advice for retina specialists ...

Belite Bio recently announced the acceptance of its New Drug Application (NDA) with priority review for tinlarebant by the Center for Drug Evaluation of China’s National Medical Products ...

A panelist discusses how integrating clinical trial data with real-world experience, patient-centered care, and shared decision-making enables retina specialists to individualize treatment plans, ...

Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial ...

AAVantgarde’s AAVB-039 gene therapy to treat Stargardt disease receives orphan drug status from FDA ...